“Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation” by Professor Dr. Rutaiwan Tohtong Department of Biochemistry, Faculty of Science Mahidol University Time:
Tag: RT
Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation
Cholangiocarcinoma (CCA) is a difficult-to-treat cancer, with limited therapeutic options and surgery being the only curative treatment. Standard chemotherapy involves gemcitabine-based therapies combined with cisplatin,
Targeting MYC at the intersection between cancer metabolism and oncoimmunology
MYC activation is a known hallmark of cancer as it governs the gene targets involved in various facets of cancer progression. Of interest, MYC
Preclinical evidence for anaplastic lymphoma kinase inhibitors as novel therapeutic treatments for cholangiocarcinoma
Introduction: Bile duct cancer (cholangiocarcinoma, CCA) has a poor prognosis for patients, and despite recent advances in targeted therapies for other cancer types, it is still
Upregulated LAMA3 modulates proliferation, adhesion, migration and epithelial‑to‑mesenchymal transition of cholangiocarcinoma cells
Cholangiocarcinoma (CCA), a bile duct cancer, is an aggressive cancer with poor prognosis. It is typically recognized by its dense extracellular matrix nature which associated
Molecularly Guided Drug Repurposing for Cholangiocarcinoma: An Integrative Bioinformatic Approach
Cholangiocarcinoma (CCA) has a complex immune microenvironment architecture, thus possessing challenges in its characterization and treatment. This study aimed to repurpose FDA-approved drugs for
In Silico Target Identification of Galangin, as an Herbal Flavonoid against Cholangiocarcinoma
Cholangiocarcinoma (CCA) is a heterogenous group of malignancies in the bile duct which proliferates aggressively. As a result, most patients are diagnosed in advanced
Analysis of laminins’ cognate receptors reveals the upregulation of ITGB4 in CCA tissues
Cholangiocarcinoma (CCA) is a rare but highly lethal cancer arising from biliary tract. Its incidence is highest in Northeast, Thailand (about 100
Molecularly Guided Drug Repurposing for Cholangiocarcinoma: An Integrative Bioinformatic Approach
Cholangiocarcinoma (CCA) has a complex immune microenvironment architecture, thus possessing challenges in its characterization and treatment. This study aimed to repurpose FDA-approved
Receptor-interacting protein kinase 1 is a key mediator in TLR3 ligand and Smac mimetic-induced cell death and suppresses TLR3 ligand-promoted invasion in cholangiocarcinoma
Cholangiocarcinoma (CCA) is a cancer of the bile duct with no effective therapy. This study explores the potential of inducing ‘apoptosis’ and